Abbott Laboratories (ABT) Common Equity (2009 - 2026)

Abbott Laboratories has disclosed Common Equity across 18 years of filings, most recently posting $51.8 billion for Q2 2026.

• In Q2 2026, Common Equity rose 1.84% year-over-year to $51.8 billion; the TTM figure through Jun 2026 stood at $51.8 billion (up 1.84% YoY), while the FY2025 annual figure was $52.8 billion, up 10.17% from the prior year.
• Common Equity came in at $51.8 billion for Q2 2026 at Abbott Laboratories, down from $52.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $52.8 billion in Q4 2025 to a low of $35.6 billion in Q1 2022.
• Average Common Equity over 5 years is $42.8 billion, with a median of $39.3 billion recorded in 2024.
• Year-over-year, Common Equity climbed 28.49% in 2025 and advanced 1.84% in 2026.
• Over 5 years, Common Equity stood at $36.9 billion in 2022, then grew by 5.21% to $38.8 billion in 2023, then rose by 23.37% to $47.9 billion in 2024, then climbed by 10.17% to $52.8 billion in 2025, then fell by 1.91% to $51.8 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $51.8 billion in Q2 2026, $52.7 billion in Q1 2026, and $52.8 billion in Q4 2025.